FWM
RGLS

Focused Wealth Management’s Regulus Therapeutics RGLS Stock Holding History

Focused Wealth Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-20,000
Closed -$163K – 1086
2021
Q2 		$163K Buy
20,000
+10,000
+100% +$112K 0.03% 200
2021
Q1 		$156K Buy
+10,000
New +$148K 0.03% 201

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
ACM
Asymmetry Capital Management San Francisco, California $188M AUM 44.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Focused Wealth Management's RGLS Position: Q3 2021 in Review

Focused Wealth Management sold out of Regulus Therapeutics (RGLS) in Q3 2021, closing a stake of 20,000 shares — an estimated $163K sold.

Focused Wealth Management first reported a position in RGLS in Q1 2021 and held it in 2 quarters. The position peaked at $163K in Q2 2021. 41 funds tracked by Wall St. Rank hold RGLS as of Q3 2021.

  • Focused Wealth Management reported no remaining Regulus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Focused Wealth Management sold 20,000 Regulus Therapeutics shares in Q3 2021, an estimated $163K.
  • Focused Wealth Management first reported a position in Regulus Therapeutics in Q1 2021 and held it in 2 quarters.
  • Focused Wealth Management's Regulus Therapeutics position peaked at $163K in Q2 2021.
  • 41 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2021.

Based on Focused Wealth Management's 13F filing for Q3 2021, filed 12 Oct 2021.